Mysimba Tablets

Name: Mysimba Tablets
SKU: 145
Availability: InStock

£95.99

Mysimba Tablets

Mysimba is a medication used to treat obesity. It contains the active ingredients Bupropion and Naltrexone which work to curb cravings and manage appetite.

Mysimba, in conjunction with lifestyle changes can help patients with a BMI of 30kg/m² or greater, manage their weight.

Mysimba is a prescription only medication however it is no longer available on the NHS. It is still possible to buy Mysimba privately.

Pack Size

Strength

Clear

SKU: N/A Category: Weight Loss

Mysimba Tablets

What is Mysimba ?

Mysimba (sometimes known as Contrave UK) is a medication prescribed to treat obesity in adults. Mysimba should be taken along with changes to diet and activity levels.

How does Mysimba work ?

The active ingredients in Mysimba are Naltrexone Hydrochloride and Bupropion Hydrochloride. Each Mysimba tablet contains 8mg Naltrexone and 90mg Bupropion. These ingredients suppress appetite, hunger and cravings.

Naltrexone Hydrochloride: Initially developed to help opioid addicts with withdrawal and cravings.

Bupropion Hydrochloride: Primarily used as a smoking cessation treatment to help smokers with nicotine cravings.

These two ingredients target the areas in the brain that regulate appetite, energy levels and cravings, making Mysimba useful tool for weight loss.

Mysimba Dosage

Mysimba UK is a prescription only medication. Exact dosage will be decided by the prescribing clinician.

However, Mysimba is typically titrated with dose gradually increasing until the optimal level is reached. A typical Mysimba dosage instruction may look something like:

Week 1: 1 tablet ONCE a day, for 7 days (one tablet a day.)

Week 2: 1 tablets TWICE a day, for 7 days (two tablets a day.)

Week 3: TWO tablets in the morning, ONE tablet in the evening (three tablets a day.)

Week 4 and beyond: TWO tablets TWICE a day (four tablets a day.)

Mysimba Side Effects

Common and very common side effects of Mysimba Include (but are not limited to):Nausea; constipation; vomiting; headaches; dizziness or vertigo; dry mouth and changes in taste sensation; tremors and feeling jittery; sleep difficulties; hot flushes; tinnitus; abdominal pain.
For full details on side effects, you should review the manufacturer’s patient information leaflet.

Is Mysimba Dangerous ?

As with any medication, there are some side effects and health risks associated with Mysimba.

Mysimba should not be used in certain patient populations such as patients with severely reduced kidney or liver function, those with high blood pressure, or those who have a history of seizures.

However when Mysimba treatment is administered properly in conjunction with a healthcare professional, it is generally a safe mediation.

Mysimba vs Orlistat

Mysimba and Orlistat have a different mechanism of action.

Orlistat:

Inhibits the absorption of dietary fats therefore reducing calories absorbed from foods. This helps create calorie deficit and aids with weight loss.

Mysimba (Bupropion & Naltrexone):

The synergistic effects of Bupropion and Naltrexone help to reduce appetite, curb cravings and prevent binge eating.

In clinical studies 28-42% of patients achieved 5% weight loss with Mysimba. Around 5% of Mysimba patients achieved 10% weight loss or greater.

Orlistat is also shown to be effective in clinical studies. Studies show Orlistat patients losing 3.9% of their body weight over the course of 12 months.

Mysimba vs Wegovy

WeGovy and Mysimba both work in different ways.

WeGovy:

Active Ingredient: Semaglutide
Is a weight loss injection, not a weight loss tablet.
Wegovy works by mimicking a hormone in your body that regulates hunger and satiety therefore reducing hunger.

Mysimba:

Oral weight loss product – It comes in tablet form.
The active ingredients (Bupropion and Naltrexone) work together to help curb cravings and prevent binge eating.

Wegovy is generally much more effective as a weight loss drug than Mysimba. Clinical trials have shown mean weight loss of 14.9% amongst obese patients being treated with WeGovy.

Clinical studies on Mysimba show a weight loss of 5% amongst 28-42% of patients.